Beam Therapeutics Inc.
BEAM · Biological Products, (No Diagnostic Substances) · 102.9M shares · +86%/yr ↑ dilution · EDGAR filings ↗
Reference price $24.58 · est. market cap ~$2.5B — last insider sale, 2026-04-01 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Clinical/early-stage biotech — base-editing clinical, heavy burn ($360M), very well-funded.
Strengths
- Liquidity — current ratio 13.1 (89th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- Exec changeRecent 8-K item 5.02 8-K ↗
- Net lossNet loss (net margin -57.2%)
- Cash burnNegative free cash flow (-360.0M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Chronic dilutionShare count +86%/yr over 4y (dilution, book value/share -87%)
- Strong balance sheetStrong balance sheet — $1.2B cash & investments, ~13 quarters of runway
- Notable holderHeld by 6 notable fund(s): FMR LLC, ARK Investment Management LLC, STATE STREET CORP +3 more (as of 2026-03-31)
- Trial readout soonUpcoming trial readout ~2026-12 — PHASE1/PHASE2 · Lymphoblastic Lymphoma
- Insider sellingInsider selling — 20 open-market sale(s) by 6 insider(s) (cluster of 6 insiders, ~$6M, last 6mo) Form 4 ↗
- Revenue declineRevenue -72.2% YoY
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Operating margin
-274.6%
Net margin
-57.2%
Return on equity
-6.5%
Return on assets
-5.4%
Revenue growth (QoQ)
-72.2%
Current ratio
13.1×
Free cash flow
-$360M
EBITDA
-$361M
Tangible book value
$1.2B
Cash & investments
$1.2B
Cash runway
13q
Stock comp / revenue
67.4%
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-17 | Ciaramella Giuseppe | Option exercise | 29K | $1.03 |
| 2026-06-17 | Ciaramella Giuseppe | Option exercise | 6.5K | $0.67 |
| 2026-04-01 | Simon Amy | Sell | 6.7K | $24.58 |
| 2026-04-01 | Bellon Christine | Sell | 6.0K | $24.58 |
| 2026-04-01 | Ciaramella Giuseppe | Sell | 12K | $24.58 |
| 2026-04-01 | Cavanagh Bethany J | Sell | 3.2K | $24.58 |
| 2026-04-01 | Evans John M. | Sell | 30K | $24.58 |
| 2026-03-31 | Evans John M. | Grant | 90K | — |
| 2026-03-31 | Bellon Christine | Grant | 20K | — |
| 2026-03-31 | Cavanagh Bethany J | Grant | 20K | — |
| 2026-03-31 | Simon Amy | Grant | 32K | — |
| 2026-03-31 | Emany Sravan Kumar | Grant | 32K | — |
| 2026-03-31 | Ciaramella Giuseppe | Grant | 40K | — |
| 2026-03-31 | Evans John M. | Option exercise | 25K | $0.67 |
| 2026-03-31 | Evans John M. | Sell | 25K | $22.76 |
| 2026-03-30 | Evans John M. | Sell | 25K | $22.37 |
| 2026-03-30 | Evans John M. | Option exercise | 25K | $0.67 |
| 2026-02-24 | Ciaramella Giuseppe | Option exercise | 35K | $17.00 |
| 2026-02-24 | Ciaramella Giuseppe | Sell | 35K | $32.00 |
| 2026-01-30 | Evans John M. | Sell | 2.9K | $29.00 |
| 2026-01-30 | Evans John M. | Option exercise | 25K | $0.67 |
| 2026-01-30 | Evans John M. | Sell | 22K | $28.27 |
| 2026-01-29 | Evans John M. | Sell | 8.7K | $29.74 |
| 2026-01-29 | Evans John M. | Option exercise | 19K | $0.67 |
| 2026-01-29 | Evans John M. | Option exercise | 5.7K | $0.67 |
| 2026-01-29 | Evans John M. | Sell | 16K | $29.19 |
| 2026-01-22 | Cavanagh Bethany J | Sell | 6.2K | $35.00 |
| 2026-01-22 | Bellon Christine | Sell | 1.4K | $34.00 |
| 2026-01-20 | Cavanagh Bethany J | Sell | 3.0K | $30.12 |
| 2026-01-15 | Bellon Christine | Sell | 16K | $34.72 |
| 2026-01-15 | Bellon Christine | Sell | 2.1K | $33.62 |
| 2026-01-15 | Bellon Christine | Sell | 559 | $35.40 |
| 2025-12-31 | Bellon Christine | Sell | 1.3K | $27.10 |
| 2025-12-31 | Emany Sravan Kumar | Sell | 6.3K | $27.10 |
| 2025-12-31 | Simon Amy | Grant | 12K | — |
| 2025-10-27 | FMR LLC | Sell | 459 | $26.68 |
| 2025-10-06 | FMR LLC | Gift | 1.2M | — |
| 2025-10-02 | Evans John M. | Option exercise | 25K | $0.67 |
| 2025-10-02 | Evans John M. | Sell | 25K | $24.63 |
| 2025-10-01 | Evans John M. | Sell | 25K | $24.51 |
| 2025-10-01 | Cavanagh Bethany J | Sell | 467 | $24.53 |
| 2025-10-01 | Bellon Christine | Sell | 373 | $24.53 |
| 2025-10-01 | Evans John M. | Option exercise | 25K | $0.67 |
| 2025-07-30 | FMR LLC | Sell | 48K | $20.50 |
| 2025-07-03 | Simon Amy | Sell | 876 | $20.12 |
| 2025-07-01 | Simon Amy | Sell | 374 | $16.94 |
| 2025-04-02 | Simon Amy | Sell | 21K | $17.73 |
| 2025-04-01 | Evans John M. | Sell | 31K | $18.35 |
| 2025-04-01 | Ciaramella Giuseppe | Sell | 7.4K | $18.35 |
| 2025-04-01 | Cavanagh Bethany J | Sell | 3.0K | $18.35 |
| 2025-04-01 | Simon Amy | Sell | 9.6K | $18.35 |
| 2025-04-01 | Bellon Christine | Sell | 5.7K | $18.35 |
| 2025-03-31 | Bellon Christine | Grant | 20K | — |
| 2025-03-31 | Simon Amy | Grant | 28K | — |
| 2025-03-31 | Ciaramella Giuseppe | Grant | 35K | — |
| 2025-03-31 | Cavanagh Bethany J | Grant | 10K | — |
| 2025-03-31 | Evans John M. | Grant | 78K | — |
| 2025-02-18 | Cavanagh Bethany J | Sell | 6.3K | $35.00 |
| 2025-02-14 | Bellon Christine | Option exercise | 508 | $7.22 |
| 2025-02-14 | Bellon Christine | Option exercise | 9.5K | $7.22 |
| 2025-02-14 | Bellon Christine | Sell | 10K | $34.00 |
| 2025-01-30 | Evans John M. | Option exercise | 30K | $0.67 |
| 2025-01-30 | Evans John M. | Sell | 30K | $26.75 |
| 2025-01-30 | Evans John M. | Sell | 200 | $27.28 |
| 2025-01-02 | Bellon Christine | Sell | 1.2K | $24.68 |
| 2025-01-02 | Cavanagh Bethany J | Sell | 1.1K | $24.68 |
| 2024-12-31 | Emany Sravan Kumar | Grant | 80K | — |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT07373639 ↗ | A Long-term Follow-up Study in Patients Who Received BEAM-101 Hemoglobinopathy, Sickle Cell Disease | — | Recruiting | 2043-02-12 |
| NCT06389877 ↗ | A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD) Alpha 1-Antitrypsin Deficiency | PHASE1/PHASE2 | Recruiting | 2028-05-01 |
| NCT05456880 ↗ | BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease Sickle Cell Disease | PHASE1/PHASE2 | Active Not Recruiting | 2028-02-01 |
| NCT06735755 ↗ | A Phase 1/2, Dose-Exploration Study to Evaluate the Safety and Efficacy of BEAM-301 in Patients With Glycogen Storage Disease Type Ia (GSDIa) Glycogen Storage Disease Type Ia | PHASE1/PHASE2 | Recruiting | 2027-12-30 |
| NCT05885464 ↗ | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) Lymphoblastic Lymphoma, T-Cell Lymphoblastic Leukemia/Lymphoma | PHASE1/PHASE2 | Active Not Recruiting | 2026-12-01 |
| NCT07304791 ↗ | This is a Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of BEAM-103 in Healthy Subjects Healthy Subjects, Healthy Participant Study | PHASE1 | Recruiting | 2026-01-29 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-06-08 | Shareholder vote | filing ↗ |
| 2026-05-07 | ResultsExhibits | filing ↗ |
| 2026-03-05 | 1.02 | filing ↗ |
| 2026-02-24 | Material agreementResultsDebt obligationExhibits | filing ↗ |
| 2026-02-12 | Material agreementExhibits | filing ↗ |
| 2026-02-05 | Exec/director change | filing ↗ |
| 2026-01-12 | ResultsReg FDExhibits | filing ↗ |
| 2025-12-11 | Acquisition/disposition | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-08 | 2026-06-03 | 0001193125-26-261693 ↗ |
| 10-Q | 2026-05-07 | 2026-03-31 | 0001193125-26-210338 ↗ |
| 8-K | 2026-05-07 | 2026-05-07 | 0001193125-26-210299 ↗ |
| 8-K | 2026-03-05 | 2026-03-02 | 0001193125-26-093914 ↗ |
| 10-K | 2026-02-24 | 2025-12-31 | 0001193125-26-065194 ↗ |
| 8-K | 2026-02-24 | 2026-02-24 | 0001193125-26-065191 ↗ |
| 8-K | 2026-02-12 | 2026-02-09 | 0001193125-26-048684 ↗ |
| 8-K | 2026-02-05 | 2026-01-31 | 0001193125-26-039365 ↗ |
| 8-K | 2026-01-12 | 2026-01-11 | 0001193125-26-009722 ↗ |
| 8-K | 2025-12-11 | 2025-12-08 | 0001193125-25-316043 ↗ |
| 8-K | 2025-11-04 | 2025-11-04 | 0001193125-25-263536 ↗ |
| 10-Q | 2025-11-04 | 2025-09-30 | 0001193125-25-263542 ↗ |